Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report issued on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Up 1.4 %

Shares of NASDAQ:AKTX opened at $2.24 on Thursday. Akari Therapeutics has a 12 month low of $1.08 and a 12 month high of $4.40. The company’s fifty day moving average price is $3.23 and its 200 day moving average price is $2.71.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.